Factors Prognostic of Visual Outcome in Patients With Subretinal Hemorrhage

Bennett, Steven R.; Folk, James C.; Blodi, Christopher F.; Klugman, Marie R.

doi:10.1016/s0002-9394(14)75575-8

Cited by 262 publications

(126 citation statements)

References 7 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Eine Untersuchung von Bennet et al [2] an 29 Augen mit großen subfovealen Blutungen und mittlerer Beobachtungsdauer von 3 Jahren ergab, dass die AMDAugen (n=12) keine Verbesserung zeigten und einen Endvisus von durchschnittlich 0,01 hatten, während die Nicht-AMDAugen (n=17) generell eine Verbesserung von 0,03 auf 0,1 erlebten. Ein unabhängi-ger Einflussfaktor für das Ergebnis war die Prominenz der Blutung.…”

Section: Natürlicher Verlauf Und Prognoseunclassified

Subretinale Blutungen

Bopp

2012

Ophthalmologe

View full text Add to dashboard Cite

Subretinal hemorrhages are a complication of various diseases which arise from the choroidal or retinal circulation. Most commonly the underlying pathology is a choroidal neovascular membrane (CNV) especially in patients with age-related macular degeneration (AMD). Less common ocular diseases are those with non-AMD-related CNV and retinal arterial macroaneurysms (RAM). Case studies have demonstrated a poor prognosis, however, a significant portion have favorable outcomes. Therefore, therapeutic decision-making is difficult. As a major difficulty in comparing different treatment modalities for submacular hemorrhages is the lack of a standardized definition of the extent of the hemorrhage. A classification for AMD-related subretinal hemorrhages including size, thickness and intraretinal location is suggested.

show abstract

Section: Natürlicher Verlauf Und Prognoseunclassified

Subretinale Blutungen

Bopp

2012

Ophthalmologe

View full text Add to dashboard Cite

show abstract

“…Subretinale Massenblutungen treten als Komplikationen neovaskulärer Prozesse des hinteren Augenabschnitts auf und sind -besonders als Folge einer neovaskulären altersbedingten Makuladegeneration -mit einer langfristig schlechteren Visusprognose assoziiert [1,3,7,11,13].…”

Section: Massenblutung Und Gerinnungshemmer Eine Unglückliche Kombinaunclassified

“…Die subretinale Massenblutung ist eine seltene, aber extrem visusbedrohende Komplikation des hinteren Augenabschnitts [3]. Unter einer subretinalen Massenblutung wird im Allgemeinen eine große und massive subretinale Blutung (.…”

Section: Definition Und Ursachen Subretinaler Massenblutungenunclassified

Submakuläre Massenblutung und Gerinnungshemmer

et al. 2012

View full text Add to dashboard Cite

Exudative age-related macular degeneration (ARMD) is one of the conditions which has been shown to be associated with a risk of massive subretinal hemorrhage. Patients with thick submacular hemorrhage complicating ARMD typically have a poor visual prognosis. Antiplatelet therapy with aspirin, clopidogrel or ticlopidine has significant benefits in the secondary prevention of fatal and non-fatal coronary and cerebrovascular events. Anticoagulation is frequently used in this elderly age group for a variety of other comorbidities including prosthetic heart valves, atrial fibrillation, ischemic heart disease, cerebrovascular disease and venous thromboembolism. However, it is a well established observation that the longer patients remain on anticoagulant therapy, the higher the cumulative risk of bleeding. Over the past years, there has been a rapidly growing body of literature concerning the risk of hemorrhagic ocular complications with ophthalmic surgery in patients receiving anticoagulant therapy. By contrast, there are still little data on the relationship between anticoagulation or antiplatelet therapy and spontaneous ocular hemorrhages and only few reports have focused on patients with ARMD. Just recently, several authors reported a strong association of anticoagulants and antiplatelet agents with the development of large subretinal hemorrhages in ARMD patients. Moreover, arterial hypertension is a high risk factor for large subretinal hemorrhages in ARMD patients receiving anticoagulants or antiplatelet agents. Physicians should be aware of an increased risk of extensive subretinal hemorrhage in ARMD patients when deciding on the initiation and duration of anticoagulant and antiplatelet therapy.

show abstract

“…These include, for example, thickness [13] and size [14,15] of the hemorrhage or the elevation of the retina due to the subretinal clot [13,15]. Until now, there is only one recent systematic investigation of the functional and anatomical benefits corresponding to different anatomical origins of the hemorrhage [16].…”

Section: Introductionmentioning

confidence: 99%

“…Until now, there is only one recent systematic investigation of the functional and anatomical benefits corresponding to different anatomical origins of the hemorrhage [16]. Most studies are case series of 10-20 eyes based only on subretinal hemorrhages (SRH), subpigment epithelial hemorrhages (SPH), and combined subretinal and subpigment epithelial hemorrhages (CH) [13,14,15,17]. In some of them, SPH were completely excluded from treatment due to a controversial indication for subretinal rtPA treatment in an isolated subpigment epithelial manifestation [18].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Vitrectomy Combined with Subretinal Recombinant Tissue Plasminogen Activator for Subretinal versus Subpigment Epithelial versus Combined Hemorrhages

Waizel

Todorova²,

Kazerounian³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Background: The aim of this study was to compare the outcomes after subretinal recombinant tissue plasminogen activator (rtPA) treatment for subretinal hemorrhages (SRH), subpigment epithelial hemorrhages (SPH), and combined subretinal and subpigment epithelial hemorrhages (CH). Methods: An observational analysis of patients treated with subretinal rtPA was performed. The primary endpoint was the assessment of visual improvement (best-corrected visual acuity, BCVA) after surgery. Secondary endpoints were evaluation of the maximal hemorrhage diameter (MHD) and central macular thickness (CMT) measured by spectral domain optical coherence tomography. Results: From a total of 83 eyes included in the study, 19 eyes showed SRH, 11 eyes SPH, and 53 eyes CH. For SRH and CH, the mean BCVA, MHD, and CMT improved significantly (p < 0.05). For patients with SPH, both the mean MHD and CMT decreased significantly (p < 0.05), whereas the mean BCVA improved only slightly after surgery (p = 0.28). Conclusion: Vitrectomy combined with subretinal rtPA injection and gas or air tamponade has a strong functional and anatomical effect on both SRH and CH and also seems to slightly improve the anatomical outcome in SPH.

show abstract

Factors Prognostic of Visual Outcome in Patients With Subretinal Hemorrhage

Cited by 262 publications

References 7 publications

Subretinale Blutungen

Subretinale Blutungen

Submakuläre Massenblutung und Gerinnungshemmer

Efficacy of Vitrectomy Combined with Subretinal Recombinant Tissue Plasminogen Activator for Subretinal versus Subpigment Epithelial versus Combined Hemorrhages

Contact Info

Product

Resources

About